

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2020 ANNUAL REPORT

Reference is made to the annual report of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2020 (“**2020 Annual Report**”) published on 29 March 2021. Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as defined in the 2020 Annual Report.

In addition to the information provided in the 2020 Annual Report, the Board would like to provide further information in relation to the pension plans of the Company.

In accordance with the rules and regulations in the PRC, the PRC-based employees of the Group shall participate in various defined contribution retirement benefit plans managed by the relevant and provincial and municipal governments in the PRC, under which the Group and its employees are required to make monthly contributions to these plans calculated as a percentage of the employees’ salaries, subject to certain ceiling. The provincial and municipal governments undertake to assume the retirement benefit obligations of all existing and future retired PRC-based employees payable under the plans described above. Other than the monthly contributions, the Group is not required to assume obligation for other pension payments or and other post-retirement benefits in respect of its employees.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
28 September 2021

As at the date of this announcement, the executive Directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin; the non-executive Directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive Directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.

This announcement, for which the Directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the “Latest Listed Company Information” page on the GEM website (<http://www.hkgem.com>) for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at www.bioteda.com.